Clinical Study Validates NuVasive Porous Interbody Implant and Synthetic Bone Graft Substitute as Cost-effective Solution for Lateral Lumbar Interbody Fusions
Spine surgeons validated clinical and economic benefits of an entirely synthetic solution in lateral lumbar fusions
SAN DIEGO, July 26, 2022 -- (Healthcare Sales & Marketing Network) -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology inno... Devices, Orthopaedic, Neurosurgery NuVasive, Attrax Putty, Modulus XLIF, interbody fusion, spine surgery
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Bone Graft | Brain | Marketing | Neurology | Neurosurgery | Orthopaedics | Pharmaceuticals | Study